Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 11 pages
Data source: Published sources
Abstract
In the 1990s the global pharmaceutical industry saw a spurt of mergers and acquisitions. Companies across the world were merging to achieve critical mass and economies of scale in all departments but more specifically in research and development. Pfizer, which had always adopted a strategy of ''organic'' growth, suddenly changed its policy and turned to the path of ''inorganic'' growth. Pfizer acquired Warner Lambert and Pharmacia on its road to becoming the biggest pharmaceutical company in the world. The major driver for these acquisitions by Pfizer was for certain key blockbuster drugs of the two acquired companies.
About
Abstract
In the 1990s the global pharmaceutical industry saw a spurt of mergers and acquisitions. Companies across the world were merging to achieve critical mass and economies of scale in all departments but more specifically in research and development. Pfizer, which had always adopted a strategy of ''organic'' growth, suddenly changed its policy and turned to the path of ''inorganic'' growth. Pfizer acquired Warner Lambert and Pharmacia on its road to becoming the biggest pharmaceutical company in the world. The major driver for these acquisitions by Pfizer was for certain key blockbuster drugs of the two acquired companies.